Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment

Cardiovascular Drugs and Therapy

Volumn 23, Issue 6, 2009, Pages 501-510

  Harangi, Mariann ^a   Seres, Ildikó ^a   Harangi, János ^b   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Research Laboratory for Chromatography   (Hungary)

Author keywords

High density lipoprotein subfractions; Paraoxonase; Statin

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVITY; FRACTIONATION; GENE DUPLICATION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; LIPID BLOOD LEVEL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; BLOOD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS;

ARYLDIALKYLPHOSPHATASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; POLYMORPHISM, GENETIC;

EID: 77649228508     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6205-4     Document Type: Review

References (99)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383-1389
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009
5. Shepherd J. Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307
6. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-2838
7. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
8. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107-113
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
10. Tavintharan S, Lim SC, Sum CF. Patients with low levels of highdensity lipoprotein cholesterol: to treat or not to treat? Singapore Med J. 2005;46:519-528
11. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves da Silva S, Khalid Z, Nordmann AJ, Zhou Q, Walter SD, Vale N, Bhatnagar N, O'Regan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009 Feb 16;338:b92. doi:10.1136/bmj.b92.
12. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:788-800.
13. Li Z, McNamara JR, Ordovas JM, Schaefer EJ. Analysis of high density lipoproteins by a modified gradient gel electrophoresis method. J Lipid Res. 1994;35:1698-1711
14. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665:408-419
15. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-Icontaining subpopulations. Biochim Biophys Acta. 1993;1169:291-300.
16. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984;259:12201-12209
17. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374
18. Salonen JT, Salonen R, Seppänen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation. 1991;84:129-139
19. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098-1105 (Pubitemid 27260329)
20. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381
21. Sweetnam PM, Bolton CH, Yarnell JW, Bainton D, Baker IA, Elwood PC, et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1994;90:769-774
22. Yu S, Yarnell JW, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis. 2003;166:331-338
23. Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic- Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem. 2007;40:310-316
24. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:847-852
25. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181-2187
26. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Schaefer EJ.Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185-2191
27. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002;90:89-94.
28. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, highdensity lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634-642
29. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med. 1989;114:250-259
30. Guérin M, Dolphin PJ, Talussot C, Gardette J, Berthé zène F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:1359-1368
31. Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol. 1995;76:129A-35A.
32. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis. 1995;114:223-234
33. Lijnen P, Echevaría-Vázquez D, Petrov V. Influence of cholesterollowering on plasma membrane lipids and function. Methods Find Exp Clin Pharmacol. 1996;18:123-136
34. Mölgaard J, Wärjerstam-Elf S, Olsson AG. Efficacy and safety of simvastatin for high-risk hypercholesterolemia. Am J Cardiol. 1999;83:1043-1048
35. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189-197
36. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol. 2002;90:689-696
37. Asztalos BF, Horvath KV,McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res. 2002;43:1701-1707
38. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515
39. Kawano M, Nagasaka S, Yagyu H, Ishibashi S. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb. 2008;15:41-46
40. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27:2236-2243
41. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, et al. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther. 2009;14:5-13.
42. HarangiM,Mirdamadi HZ, Seres I, Sztanek F,MornárM, Kassai A, et al. Atorvastatin effect on the distribution of HDL subfractions and human paraoxonase activity. Transl Res. 2009;153:190-198
43. Rizzo M, Berneis K. The clinical relevance of low-densitylipoproteins size modulation by statins. Cardiovasc Drugs Ther. 2006;20:205-217
44. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol. 2002;13:357-362
45. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33:832-839
46. La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact. 1993;87:25-34.
47. Rainwater DL, Rutherford S, Dyer TD, Rainwater ED, Cole SA, Vandeberg JL, et al. Determinants of variation in human serum paraoxonase activity. Heredity. 2009;102:147-154
48. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol. 2009;54:1238-1245
49. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S. Ben Hamda K, Ben Farhat M, Miled A, Hammami M. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem. 2009;42:771-776
50. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000;20:516-521
51. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239-1247
52. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998;423:57-60.
53. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-1276
54. Harangi M, Seres I, Magyar MT, Csipo I, Sipka S, Valikovics A, et al. Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc Dis. 2008;25:122-128
55. She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, et al. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res. 2009;104:1160-1168
56. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;122:265-268
57. Atmeh RF, Shepherd J, Packard CJ. Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. Biochim Biophys Acta. 1983;751:175-188
58. Moren X, Deakin SP, Liu ML, Taskinen MR, James RW. HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res. 2008;49:1246-1253
59. Paragh G, Harangi M, Seres I. Effect of lipid lowering medications on PON1. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in disease development and xenobiotic metabolism. Springer; 2008. pp. 251-266
60. Tomás M, Sentí M, García-Faria F, Vila J, Rorrents A, Covas M, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patiens. Arterioscler Thromb Vasc Biol. 2000;20:2113-2119
61. Balogh Z, Fülöp P, Seres I, Harangi M, Katona E, Kosztáczky B, et al. Effects of simvastatin on serum paraoxonase activity. Clin Drug Invest. 2001;21:505-510
62. Tsimihodimos V, Karabina SAP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIa and type IIb. Arterioscler Throm Vasc Biol. 2002;22:306-311
63. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis. 2002;164:179-185
64. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol reulatory element-binding protein-2. Arterioscler Throm Vasc Biol. 2003;23:2083-2089
65. Kural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the antioxidant system in patients with dyslipidemia. Coron Artery Dis. 2004;15:277-283
66. Paragh G, Törcsik D, Seres I, Harangi M, Illyés L, Balogh Z, et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin. 2004;20:1321-1327
67. Harangi M, Seres I, Varga Z, Emri G, Szilvássy Z, Paragh G, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol. 2004;60:685-691
68. Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, et al. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin. 2005 May;21(5):777-784
69. Kassai A, Illyés L, Mirdamadi HZ, Seres I, Kalmár T, Audikovszky M, et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem. 2007;40:1-5.
70. Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, Van der Bom JG, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin. 2007;23:2235-2240
71. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, et al. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch Med Res. 2007;38: 403-410
72. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol. 2008;66:366-374
73. Ota K, Suehiro T, Arii K, Ikeda Y, Kumon Y, Osaki F, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005;54:142-150
74. Gouédard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol. 2003;63:945-956
75. Malin R, Laaksonen R, Knuuti J, Janatuinen T, Vesalainen R, Nuutila P, et al. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics. 2001;11:625-633
76. Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase 1 gene promoter polymorphism C-107 T and statin. Pharmacogen Genom. 2007;17:451-457
77. Fu R, Sun YM, Su Y, Wu Y, Luan Y. Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2008;35:982-983
78. Lindgren FT, Elliott HA, Gofman JW. The ultracentrifugal characterization and isolation of human blood lipids andlipoproteins, with applications to the study of atherosclerosis. J Phys Colloid Chem. 1951;55:80-93.
79. Kirstein P, Carlson K. Determination of the cholesterol content of high density lipoprotein subfractions HDL2 and HDL3, without contamination of Lp(a), in human plasma. Clin Chim Acta. 1981;113:123-134
80. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388
81. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206-1223
82. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006;26:787-802.
83. Warnick GR, McNamara JR, Boggess CN, Clendenen F, Williams PT. Landolt CC.Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med. 2006;26:803-846
84. Waymack PP. A Perspective on HDL-LDL Subclass, Subspecies and Subfraction Analyses and Challenges for Standardization. http:// www.fda.gov/ohrms/dockets/ ac/06/slides/2006-4263s1-04-Waymack-Guest.pdf Accessed 6 Dec 2006.
85. Fisman EZ, Adler Y, Tenenbaum A. Statins research unfinished saga: desirability versus feasibility. Cardiovasc Diabetol. 2005; 4:8.
86. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Wedel H; Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Atheroscler Suppl. 2004;5:81-87
87. Sirtori CR. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther. 1993;60: 431-459
88. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb. 2008;15:52-62.
89. Vincent-Viry M, Sass C, Bastien S, Aguillon D, Siest G, Visvikis S. PON1-192 phenotype and genotype assessments in 918 subjects of the Stanislas Cohort Study. Clin Chem Lab Med. 2003;41:535-540
90. Paragh G, Seres I, Harangi M, Pocsai Z, Asztalos L, Locsey L, et al. Discordance in Human Paraoxonase-1 Gene between Phenotypes and Genotypes in Chronic Kidney Disease. Nephron Clin Pract. 2009;113:46-53.
91. Camps J, Marsillach J, Joven J. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Rev Med Chem. 2009;9:911-920
92. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes. 1990;39:1257-1263
93. Wang WQ, Merriam DL, Moses AS, Francis GA. Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J Biol Chem. 1998;273:17391-17398
94. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181:S462-72.
95. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res. 1996;37:2662-2674
96. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. HDL loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103:2283-2288
97. Superko HR, Enas EA, Kotha P, Bhat NK, Garrett B. Highdensity lipoprotein subclass distribution in individuals of Asian Indian descent: the National Asian Indian Heart Disease Project. Prev Cardiol. 2005;8:81-86
98. Martinelli N, Girelli D, Olivieri O, Guarini P, Bassi A, Trabetti E, et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med. 2009;47:432-440
99. Mackness B, Mackness M. High-density lipoprotein: why all the fuss? Ann Clin Biochem. 2009;46:5-7.